Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
33,560
archived clinical trials in
Neurology

16-week Efficacy and 3-year Safety, Tolerability and Efficacy of Secukinumab in Active Ankylosing Spondylitis Patients
A Randomized, Double-blind, Placebo-controlled Phase III Study of Secukinumab to Demonstrate the Efficacy at 16 Weeks and to Assess the Long-term Safety, Tolerability and Efficacy up to 3 Years in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigational Site
mi
from
Charleston, SC
16-week Efficacy and 3-year Safety, Tolerability and Efficacy of Secukinumab in Active Ankylosing Spondylitis Patients
A Randomized, Double-blind, Placebo-controlled Phase III Study of Secukinumab to Demonstrate the Efficacy at 16 Weeks and to Assess the Long-term Safety, Tolerability and Efficacy up to 3 Years in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigational Site
mi
from
Charleston, SC
Click here to add this to my saved trials
16-week Efficacy and 3-year Safety, Tolerability and Efficacy of Secukinumab in Active Ankylosing Spondylitis Patients
A Randomized, Double-blind, Placebo-controlled Phase III Study of Secukinumab to Demonstrate the Efficacy at 16 Weeks and to Assess the Long-term Safety, Tolerability and Efficacy up to 3 Years in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Mesa, AZ
16-week Efficacy and 3-year Safety, Tolerability and Efficacy of Secukinumab in Active Ankylosing Spondylitis Patients
A Randomized, Double-blind, Placebo-controlled Phase III Study of Secukinumab to Demonstrate the Efficacy at 16 Weeks and to Assess the Long-term Safety, Tolerability and Efficacy up to 3 Years in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Mesa, AZ
Click here to add this to my saved trials
16-week Efficacy and 3-year Safety, Tolerability and Efficacy of Secukinumab in Active Ankylosing Spondylitis Patients
A Randomized, Double-blind, Placebo-controlled Phase III Study of Secukinumab to Demonstrate the Efficacy at 16 Weeks and to Assess the Long-term Safety, Tolerability and Efficacy up to 3 Years in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Palm Harbor, FL
16-week Efficacy and 3-year Safety, Tolerability and Efficacy of Secukinumab in Active Ankylosing Spondylitis Patients
A Randomized, Double-blind, Placebo-controlled Phase III Study of Secukinumab to Demonstrate the Efficacy at 16 Weeks and to Assess the Long-term Safety, Tolerability and Efficacy up to 3 Years in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Palm Harbor, FL
Click here to add this to my saved trials
16-week Efficacy and 3-year Safety, Tolerability and Efficacy of Secukinumab in Active Ankylosing Spondylitis Patients
A Randomized, Double-blind, Placebo-controlled Phase III Study of Secukinumab to Demonstrate the Efficacy at 16 Weeks and to Assess the Long-term Safety, Tolerability and Efficacy up to 3 Years in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Pembroke Pines, FL
16-week Efficacy and 3-year Safety, Tolerability and Efficacy of Secukinumab in Active Ankylosing Spondylitis Patients
A Randomized, Double-blind, Placebo-controlled Phase III Study of Secukinumab to Demonstrate the Efficacy at 16 Weeks and to Assess the Long-term Safety, Tolerability and Efficacy up to 3 Years in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Pembroke Pines, FL
Click here to add this to my saved trials
16-week Efficacy and 3-year Safety, Tolerability and Efficacy of Secukinumab in Active Ankylosing Spondylitis Patients
A Randomized, Double-blind, Placebo-controlled Phase III Study of Secukinumab to Demonstrate the Efficacy at 16 Weeks and to Assess the Long-term Safety, Tolerability and Efficacy up to 3 Years in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Passaic, NJ
16-week Efficacy and 3-year Safety, Tolerability and Efficacy of Secukinumab in Active Ankylosing Spondylitis Patients
A Randomized, Double-blind, Placebo-controlled Phase III Study of Secukinumab to Demonstrate the Efficacy at 16 Weeks and to Assess the Long-term Safety, Tolerability and Efficacy up to 3 Years in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Passaic, NJ
Click here to add this to my saved trials
16-week Efficacy and 3-year Safety, Tolerability and Efficacy of Secukinumab in Active Ankylosing Spondylitis Patients
A Randomized, Double-blind, Placebo-controlled Phase III Study of Secukinumab to Demonstrate the Efficacy at 16 Weeks and to Assess the Long-term Safety, Tolerability and Efficacy up to 3 Years in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigational Site
mi
from
Austin, TX
16-week Efficacy and 3-year Safety, Tolerability and Efficacy of Secukinumab in Active Ankylosing Spondylitis Patients
A Randomized, Double-blind, Placebo-controlled Phase III Study of Secukinumab to Demonstrate the Efficacy at 16 Weeks and to Assess the Long-term Safety, Tolerability and Efficacy up to 3 Years in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigational Site
mi
from
Austin, TX
Click here to add this to my saved trials
Schema, Emotion and Behavior-Based Therapy for School Children
Cognitive Behavioral Therapy for Core Autism Symptoms in School-Age Children
Status: Enrolling
Updated:  12/31/1969
Jeffrey Wood
mi
from
Los Angeles, CA
Schema, Emotion and Behavior-Based Therapy for School Children
Cognitive Behavioral Therapy for Core Autism Symptoms in School-Age Children
Status: Enrolling
Updated: 12/31/1969
Jeffrey Wood
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Practice-Based Trial of Home BP Telemonitoring Among Minority Stroke Survivors
Practice-Based Trial of Home BP Telemonitoring Among Minority Stroke Survivors
Status: Enrolling
Updated:  12/31/1969
NYU School of Medicine
mi
from
New York, NY
Practice-Based Trial of Home BP Telemonitoring Among Minority Stroke Survivors
Practice-Based Trial of Home BP Telemonitoring Among Minority Stroke Survivors
Status: Enrolling
Updated: 12/31/1969
NYU School of Medicine
mi
from
New York, NY
Click here to add this to my saved trials
Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study of Autologous MSC-NTF Cells in Patients With ALS
A Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study to Evaluate Safety and Efficacy of Transplantation of Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors (MSC-NTF) in Patients With ALS
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study of Autologous MSC-NTF Cells in Patients With ALS
A Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study to Evaluate Safety and Efficacy of Transplantation of Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors (MSC-NTF) in Patients With ALS
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study of Autologous MSC-NTF Cells in Patients With ALS
A Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study to Evaluate Safety and Efficacy of Transplantation of Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors (MSC-NTF) in Patients With ALS
Status: Enrolling
Updated:  12/31/1969
UMass Medical School
mi
from
Worcester, MA
Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study of Autologous MSC-NTF Cells in Patients With ALS
A Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study to Evaluate Safety and Efficacy of Transplantation of Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors (MSC-NTF) in Patients With ALS
Status: Enrolling
Updated: 12/31/1969
UMass Medical School
mi
from
Worcester, MA
Click here to add this to my saved trials
Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study of Autologous MSC-NTF Cells in Patients With ALS
A Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study to Evaluate Safety and Efficacy of Transplantation of Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors (MSC-NTF) in Patients With ALS
Status: Enrolling
Updated:  12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study of Autologous MSC-NTF Cells in Patients With ALS
A Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study to Evaluate Safety and Efficacy of Transplantation of Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors (MSC-NTF) in Patients With ALS
Status: Enrolling
Updated: 12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Phase 2 Clinical Trial of SGS-742 Therapy in Succinic Semialdehyde Dehydrogenase Deficiency
Phase 2 Clinical Trial of SGS-742 Therapy in Succinic Semialdehyde Dehydrogenase Deficiency
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Phase 2 Clinical Trial of SGS-742 Therapy in Succinic Semialdehyde Dehydrogenase Deficiency
Phase 2 Clinical Trial of SGS-742 Therapy in Succinic Semialdehyde Dehydrogenase Deficiency
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Phase 2 Clinical Trial of SGS-742 Therapy in Succinic Semialdehyde Dehydrogenase Deficiency
Phase 2 Clinical Trial of SGS-742 Therapy in Succinic Semialdehyde Dehydrogenase Deficiency
Status: Enrolling
Updated:  12/31/1969
Washington State University
mi
from
Pullman, WA
Phase 2 Clinical Trial of SGS-742 Therapy in Succinic Semialdehyde Dehydrogenase Deficiency
Phase 2 Clinical Trial of SGS-742 Therapy in Succinic Semialdehyde Dehydrogenase Deficiency
Status: Enrolling
Updated: 12/31/1969
Washington State University
mi
from
Pullman, WA
Click here to add this to my saved trials
Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy
A Phase 2 Study Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy
A Phase 2 Study Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
18F-DOPA-PET in Planning Surgery in Patients With Gliomas
Evaluating the Impact of 18F-DOPA-PET on Neurosurgical Planning for Gliomas
Status: Enrolling
Updated:  12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
18F-DOPA-PET in Planning Surgery in Patients With Gliomas
Evaluating the Impact of 18F-DOPA-PET on Neurosurgical Planning for Gliomas
Status: Enrolling
Updated: 12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Effects of Gilenya (Fingolimod) on Thalamus Pathology and Cognitive Impairment in Patients With Relapsing Forms of Multiple Sclerosis
Open-label, Single-blinded, Observational, Prospective, 24-months, Longitudinal, Controlled Study to Assess the Efficacy of Gilenya® on Development of Thalamus Pathology and Cognitive Impairment in Patients With Relapsing Forms of Multiple Sclerosis.
Status: Enrolling
Updated:  12/31/1969
Buffalo Neuroimaging Analysis Center
mi
from
Buffalo, NY
Effects of Gilenya (Fingolimod) on Thalamus Pathology and Cognitive Impairment in Patients With Relapsing Forms of Multiple Sclerosis
Open-label, Single-blinded, Observational, Prospective, 24-months, Longitudinal, Controlled Study to Assess the Efficacy of Gilenya® on Development of Thalamus Pathology and Cognitive Impairment in Patients With Relapsing Forms of Multiple Sclerosis.
Status: Enrolling
Updated: 12/31/1969
Buffalo Neuroimaging Analysis Center
mi
from
Buffalo, NY
Click here to add this to my saved trials
Center for Stroke Disparities Solution - Community Transitions Intervention
Center for Stroke Disparities Solution (CSDS) Project II: Community Transitions Intervention (CTI)
Status: Enrolling
Updated:  12/31/1969
Visiting Nurse Service of New York
mi
from
New York, NY
Center for Stroke Disparities Solution - Community Transitions Intervention
Center for Stroke Disparities Solution (CSDS) Project II: Community Transitions Intervention (CTI)
Status: Enrolling
Updated: 12/31/1969
Visiting Nurse Service of New York
mi
from
New York, NY
Click here to add this to my saved trials
Psychotherapy for Anxiety in Children With Autism Spectrum Disorder
2/3 Treatment of Anxiety in Autism Spectrum Disorder
Status: Enrolling
Updated:  12/31/1969
Rothman Center for Neuropsychiatry, University of South Florida
mi
from
Saint Petersburg, FL
Psychotherapy for Anxiety in Children With Autism Spectrum Disorder
2/3 Treatment of Anxiety in Autism Spectrum Disorder
Status: Enrolling
Updated: 12/31/1969
Rothman Center for Neuropsychiatry, University of South Florida
mi
from
Saint Petersburg, FL
Click here to add this to my saved trials
Post-operative Analgesia in Elective, Soft-tissue Hand Surgery
Post-operative Analgesia in Elective, Soft-tissue Hand Surgery: A Randomized, Double Blind Comparison of Acetaminophen/Ibuprofen Versus Acetaminophen/Hydrocodone
Status: Enrolling
Updated:  12/31/1969
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Post-operative Analgesia in Elective, Soft-tissue Hand Surgery
Post-operative Analgesia in Elective, Soft-tissue Hand Surgery: A Randomized, Double Blind Comparison of Acetaminophen/Ibuprofen Versus Acetaminophen/Hydrocodone
Status: Enrolling
Updated: 12/31/1969
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
PET Imaging Study of Neurochemical and Autonomic Disorders in Multiple System Atrophy (MSA)
Pathogenesis and Diagnosis of Multiple System Atrophy (MSA): PET Study of Neurochemical and Autonomic Disorders in MSA
Status: Enrolling
Updated:  12/31/1969
University of Michigan - Department of Neurology
mi
from
Ann Arbor, MI
PET Imaging Study of Neurochemical and Autonomic Disorders in Multiple System Atrophy (MSA)
Pathogenesis and Diagnosis of Multiple System Atrophy (MSA): PET Study of Neurochemical and Autonomic Disorders in MSA
Status: Enrolling
Updated: 12/31/1969
University of Michigan - Department of Neurology
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Pivotal Response Treatment Package for Young Children With Autism
Pivotal Response Treatment Package for Young Children With Autism
Status: Enrolling
Updated:  12/31/1969
Stanford University School of Medicine
mi
from
Stanford, CA
Pivotal Response Treatment Package for Young Children With Autism
Pivotal Response Treatment Package for Young Children With Autism
Status: Enrolling
Updated: 12/31/1969
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
Sustainable Methods, Algorithms, and Research Tools for Delivering Optimal Care Study
Sustainable Methods, Algorithms, and Research Tools for Delivering Optimal Care Study (SMART DOCS)
Status: Enrolling
Updated:  12/31/1969
Stanford Sleep Clinic, Stanford University Center for Sleep Science and Medicine
mi
from
Redwood City, CA
Sustainable Methods, Algorithms, and Research Tools for Delivering Optimal Care Study
Sustainable Methods, Algorithms, and Research Tools for Delivering Optimal Care Study (SMART DOCS)
Status: Enrolling
Updated: 12/31/1969
Stanford Sleep Clinic, Stanford University Center for Sleep Science and Medicine
mi
from
Redwood City, CA
Click here to add this to my saved trials
A Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity in Patients With Relapsing-remitting Multiple Sclerosis
A Randomized, Partially Blind, Placebo-controlled, Proof-of-concept Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity as Measured by Brain MRI Scans in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Long Beach, CA
A Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity in Patients With Relapsing-remitting Multiple Sclerosis
A Randomized, Partially Blind, Placebo-controlled, Proof-of-concept Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity as Measured by Brain MRI Scans in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Long Beach, CA
Click here to add this to my saved trials
A Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity in Patients With Relapsing-remitting Multiple Sclerosis
A Randomized, Partially Blind, Placebo-controlled, Proof-of-concept Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity as Measured by Brain MRI Scans in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
San Diego, CA
A Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity in Patients With Relapsing-remitting Multiple Sclerosis
A Randomized, Partially Blind, Placebo-controlled, Proof-of-concept Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity as Measured by Brain MRI Scans in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
San Diego, CA
Click here to add this to my saved trials
A Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity in Patients With Relapsing-remitting Multiple Sclerosis
A Randomized, Partially Blind, Placebo-controlled, Proof-of-concept Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity as Measured by Brain MRI Scans in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Hradec Kralove,
A Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity in Patients With Relapsing-remitting Multiple Sclerosis
A Randomized, Partially Blind, Placebo-controlled, Proof-of-concept Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity as Measured by Brain MRI Scans in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Hradec Kralove,
Click here to add this to my saved trials
Examining Tolerance to CNS Stimulants in ADHD
Examining Tolerance to CNS Stimulants in ADHD
Status: Enrolling
Updated:  12/31/1969
Florida International University Center for Children and Families
mi
from
Miami, FL
Examining Tolerance to CNS Stimulants in ADHD
Examining Tolerance to CNS Stimulants in ADHD
Status: Enrolling
Updated: 12/31/1969
Florida International University Center for Children and Families
mi
from
Miami, FL
Click here to add this to my saved trials
Study Evaluating Rapid Infusion Rituximab in Patients With Autoimmune Diseases
Study Evaluating Rapid Infusion Rituximab in Patients With Autoimmune Diseases
Status: Enrolling
Updated:  12/31/1969
Wake Forest Baptist Medical Center
mi
from
Winston-Salem, NC
Study Evaluating Rapid Infusion Rituximab in Patients With Autoimmune Diseases
Study Evaluating Rapid Infusion Rituximab in Patients With Autoimmune Diseases
Status: Enrolling
Updated: 12/31/1969
Wake Forest Baptist Medical Center
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Nutrition and Aerobic Exercise in Chronic Stroke
Aerobic Training to Improve Energy Utilization and Antioxidant Capacity in Stroke
Status: Enrolling
Updated:  12/31/1969
Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD
mi
from
Baltimore, MD
Nutrition and Aerobic Exercise in Chronic Stroke
Aerobic Training to Improve Energy Utilization and Antioxidant Capacity in Stroke
Status: Enrolling
Updated: 12/31/1969
Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD
mi
from
Baltimore, MD
Click here to add this to my saved trials
Nutrition and Aerobic Exercise in Chronic Stroke
Aerobic Training to Improve Energy Utilization and Antioxidant Capacity in Stroke
Status: Enrolling
Updated:  12/31/1969
Atlanta VA Medical and Rehab Center, Decatur, GA
mi
from
Decatur, GA
Nutrition and Aerobic Exercise in Chronic Stroke
Aerobic Training to Improve Energy Utilization and Antioxidant Capacity in Stroke
Status: Enrolling
Updated: 12/31/1969
Atlanta VA Medical and Rehab Center, Decatur, GA
mi
from
Decatur, GA
Click here to add this to my saved trials
Evaluating Long Term Safety of Lacosamide (LCM) to Carbamazepine Controlled-release (CBZ-CR); Initial Monotherapy in Epilepsy Subjects 16 Years and Older
A Multicenter, Double-blind, Double-dummy, Follow up Study Evaluating the Long-term Safety of Lacosamide in Comparison With Controlled-release Carbamazepine Used as Monotherapy in Subjects With Partial-onset or Generalized Tonic-clonic Seizures ≥16 Years of Age Coming From the SP0993 Study.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Alabaster, AL
Evaluating Long Term Safety of Lacosamide (LCM) to Carbamazepine Controlled-release (CBZ-CR); Initial Monotherapy in Epilepsy Subjects 16 Years and Older
A Multicenter, Double-blind, Double-dummy, Follow up Study Evaluating the Long-term Safety of Lacosamide in Comparison With Controlled-release Carbamazepine Used as Monotherapy in Subjects With Partial-onset or Generalized Tonic-clonic Seizures ≥16 Years of Age Coming From the SP0993 Study.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Alabaster, AL
Click here to add this to my saved trials
Evaluating Long Term Safety of Lacosamide (LCM) to Carbamazepine Controlled-release (CBZ-CR); Initial Monotherapy in Epilepsy Subjects 16 Years and Older
A Multicenter, Double-blind, Double-dummy, Follow up Study Evaluating the Long-term Safety of Lacosamide in Comparison With Controlled-release Carbamazepine Used as Monotherapy in Subjects With Partial-onset or Generalized Tonic-clonic Seizures ≥16 Years of Age Coming From the SP0993 Study.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Huntsville, AL
Evaluating Long Term Safety of Lacosamide (LCM) to Carbamazepine Controlled-release (CBZ-CR); Initial Monotherapy in Epilepsy Subjects 16 Years and Older
A Multicenter, Double-blind, Double-dummy, Follow up Study Evaluating the Long-term Safety of Lacosamide in Comparison With Controlled-release Carbamazepine Used as Monotherapy in Subjects With Partial-onset or Generalized Tonic-clonic Seizures ≥16 Years of Age Coming From the SP0993 Study.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Huntsville, AL
Click here to add this to my saved trials
Evaluating Long Term Safety of Lacosamide (LCM) to Carbamazepine Controlled-release (CBZ-CR); Initial Monotherapy in Epilepsy Subjects 16 Years and Older
A Multicenter, Double-blind, Double-dummy, Follow up Study Evaluating the Long-term Safety of Lacosamide in Comparison With Controlled-release Carbamazepine Used as Monotherapy in Subjects With Partial-onset or Generalized Tonic-clonic Seizures ≥16 Years of Age Coming From the SP0993 Study.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Little Rock, AR
Evaluating Long Term Safety of Lacosamide (LCM) to Carbamazepine Controlled-release (CBZ-CR); Initial Monotherapy in Epilepsy Subjects 16 Years and Older
A Multicenter, Double-blind, Double-dummy, Follow up Study Evaluating the Long-term Safety of Lacosamide in Comparison With Controlled-release Carbamazepine Used as Monotherapy in Subjects With Partial-onset or Generalized Tonic-clonic Seizures ≥16 Years of Age Coming From the SP0993 Study.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Little Rock, AR
Click here to add this to my saved trials
Evaluating Long Term Safety of Lacosamide (LCM) to Carbamazepine Controlled-release (CBZ-CR); Initial Monotherapy in Epilepsy Subjects 16 Years and Older
A Multicenter, Double-blind, Double-dummy, Follow up Study Evaluating the Long-term Safety of Lacosamide in Comparison With Controlled-release Carbamazepine Used as Monotherapy in Subjects With Partial-onset or Generalized Tonic-clonic Seizures ≥16 Years of Age Coming From the SP0993 Study.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Panama City, FL
Evaluating Long Term Safety of Lacosamide (LCM) to Carbamazepine Controlled-release (CBZ-CR); Initial Monotherapy in Epilepsy Subjects 16 Years and Older
A Multicenter, Double-blind, Double-dummy, Follow up Study Evaluating the Long-term Safety of Lacosamide in Comparison With Controlled-release Carbamazepine Used as Monotherapy in Subjects With Partial-onset or Generalized Tonic-clonic Seizures ≥16 Years of Age Coming From the SP0993 Study.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Panama City, FL
Click here to add this to my saved trials
Evaluating Long Term Safety of Lacosamide (LCM) to Carbamazepine Controlled-release (CBZ-CR); Initial Monotherapy in Epilepsy Subjects 16 Years and Older
A Multicenter, Double-blind, Double-dummy, Follow up Study Evaluating the Long-term Safety of Lacosamide in Comparison With Controlled-release Carbamazepine Used as Monotherapy in Subjects With Partial-onset or Generalized Tonic-clonic Seizures ≥16 Years of Age Coming From the SP0993 Study.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Port Charlotte, FL
Evaluating Long Term Safety of Lacosamide (LCM) to Carbamazepine Controlled-release (CBZ-CR); Initial Monotherapy in Epilepsy Subjects 16 Years and Older
A Multicenter, Double-blind, Double-dummy, Follow up Study Evaluating the Long-term Safety of Lacosamide in Comparison With Controlled-release Carbamazepine Used as Monotherapy in Subjects With Partial-onset or Generalized Tonic-clonic Seizures ≥16 Years of Age Coming From the SP0993 Study.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Port Charlotte, FL
Click here to add this to my saved trials
Evaluating Long Term Safety of Lacosamide (LCM) to Carbamazepine Controlled-release (CBZ-CR); Initial Monotherapy in Epilepsy Subjects 16 Years and Older
A Multicenter, Double-blind, Double-dummy, Follow up Study Evaluating the Long-term Safety of Lacosamide in Comparison With Controlled-release Carbamazepine Used as Monotherapy in Subjects With Partial-onset or Generalized Tonic-clonic Seizures ≥16 Years of Age Coming From the SP0993 Study.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Raleigh, NC
Evaluating Long Term Safety of Lacosamide (LCM) to Carbamazepine Controlled-release (CBZ-CR); Initial Monotherapy in Epilepsy Subjects 16 Years and Older
A Multicenter, Double-blind, Double-dummy, Follow up Study Evaluating the Long-term Safety of Lacosamide in Comparison With Controlled-release Carbamazepine Used as Monotherapy in Subjects With Partial-onset or Generalized Tonic-clonic Seizures ≥16 Years of Age Coming From the SP0993 Study.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Raleigh, NC
Click here to add this to my saved trials
Evaluating Long Term Safety of Lacosamide (LCM) to Carbamazepine Controlled-release (CBZ-CR); Initial Monotherapy in Epilepsy Subjects 16 Years and Older
A Multicenter, Double-blind, Double-dummy, Follow up Study Evaluating the Long-term Safety of Lacosamide in Comparison With Controlled-release Carbamazepine Used as Monotherapy in Subjects With Partial-onset or Generalized Tonic-clonic Seizures ≥16 Years of Age Coming From the SP0993 Study.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Oklahoma City, OK
Evaluating Long Term Safety of Lacosamide (LCM) to Carbamazepine Controlled-release (CBZ-CR); Initial Monotherapy in Epilepsy Subjects 16 Years and Older
A Multicenter, Double-blind, Double-dummy, Follow up Study Evaluating the Long-term Safety of Lacosamide in Comparison With Controlled-release Carbamazepine Used as Monotherapy in Subjects With Partial-onset or Generalized Tonic-clonic Seizures ≥16 Years of Age Coming From the SP0993 Study.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Evaluating Long Term Safety of Lacosamide (LCM) to Carbamazepine Controlled-release (CBZ-CR); Initial Monotherapy in Epilepsy Subjects 16 Years and Older
A Multicenter, Double-blind, Double-dummy, Follow up Study Evaluating the Long-term Safety of Lacosamide in Comparison With Controlled-release Carbamazepine Used as Monotherapy in Subjects With Partial-onset or Generalized Tonic-clonic Seizures ≥16 Years of Age Coming From the SP0993 Study.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Mansfield, TX
Evaluating Long Term Safety of Lacosamide (LCM) to Carbamazepine Controlled-release (CBZ-CR); Initial Monotherapy in Epilepsy Subjects 16 Years and Older
A Multicenter, Double-blind, Double-dummy, Follow up Study Evaluating the Long-term Safety of Lacosamide in Comparison With Controlled-release Carbamazepine Used as Monotherapy in Subjects With Partial-onset or Generalized Tonic-clonic Seizures ≥16 Years of Age Coming From the SP0993 Study.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Mansfield, TX
Click here to add this to my saved trials
Evaluating Long Term Safety of Lacosamide (LCM) to Carbamazepine Controlled-release (CBZ-CR); Initial Monotherapy in Epilepsy Subjects 16 Years and Older
A Multicenter, Double-blind, Double-dummy, Follow up Study Evaluating the Long-term Safety of Lacosamide in Comparison With Controlled-release Carbamazepine Used as Monotherapy in Subjects With Partial-onset or Generalized Tonic-clonic Seizures ≥16 Years of Age Coming From the SP0993 Study.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Madison, WI
Evaluating Long Term Safety of Lacosamide (LCM) to Carbamazepine Controlled-release (CBZ-CR); Initial Monotherapy in Epilepsy Subjects 16 Years and Older
A Multicenter, Double-blind, Double-dummy, Follow up Study Evaluating the Long-term Safety of Lacosamide in Comparison With Controlled-release Carbamazepine Used as Monotherapy in Subjects With Partial-onset or Generalized Tonic-clonic Seizures ≥16 Years of Age Coming From the SP0993 Study.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Madison, WI
Click here to add this to my saved trials
Evaluating Long Term Safety of Lacosamide (LCM) to Carbamazepine Controlled-release (CBZ-CR); Initial Monotherapy in Epilepsy Subjects 16 Years and Older
A Multicenter, Double-blind, Double-dummy, Follow up Study Evaluating the Long-term Safety of Lacosamide in Comparison With Controlled-release Carbamazepine Used as Monotherapy in Subjects With Partial-onset or Generalized Tonic-clonic Seizures ≥16 Years of Age Coming From the SP0993 Study.
Status: Enrolling
Updated:  12/31/1969
104
mi
from
Chatswood,
Evaluating Long Term Safety of Lacosamide (LCM) to Carbamazepine Controlled-release (CBZ-CR); Initial Monotherapy in Epilepsy Subjects 16 Years and Older
A Multicenter, Double-blind, Double-dummy, Follow up Study Evaluating the Long-term Safety of Lacosamide in Comparison With Controlled-release Carbamazepine Used as Monotherapy in Subjects With Partial-onset or Generalized Tonic-clonic Seizures ≥16 Years of Age Coming From the SP0993 Study.
Status: Enrolling
Updated: 12/31/1969
104
mi
from
Chatswood,
Click here to add this to my saved trials
Anger Self-Management in Traumatic Brain Injury
Anger Self-Management in Post-Acute Traumatic Brain Injury: Clinical Trial
Status: Enrolling
Updated:  12/31/1969
Craig Hospital
mi
from
Englewood, CO
Anger Self-Management in Traumatic Brain Injury
Anger Self-Management in Post-Acute Traumatic Brain Injury: Clinical Trial
Status: Enrolling
Updated: 12/31/1969
Craig Hospital
mi
from
Englewood, CO
Click here to add this to my saved trials
Anger Self-Management in Traumatic Brain Injury
Anger Self-Management in Post-Acute Traumatic Brain Injury: Clinical Trial
Status: Enrolling
Updated:  12/31/1969
Data Cordinating Center
mi
from
Englewood, CO
Anger Self-Management in Traumatic Brain Injury
Anger Self-Management in Post-Acute Traumatic Brain Injury: Clinical Trial
Status: Enrolling
Updated: 12/31/1969
Data Cordinating Center
mi
from
Englewood, CO
Click here to add this to my saved trials
Anger Self-Management in Traumatic Brain Injury
Anger Self-Management in Post-Acute Traumatic Brain Injury: Clinical Trial
Status: Enrolling
Updated:  12/31/1969
Moss Rehabilitation Research Institue
mi
from
Elkins Park, PA
Anger Self-Management in Traumatic Brain Injury
Anger Self-Management in Post-Acute Traumatic Brain Injury: Clinical Trial
Status: Enrolling
Updated: 12/31/1969
Moss Rehabilitation Research Institue
mi
from
Elkins Park, PA
Click here to add this to my saved trials
Phase IV-Cervical Dystonia-INTEREST IN CD2
An International Observational Prospective Study On Long-Term Response To Botulinum Toxin Type A (BoNT-A) Injections In Subjects Suffering From Idiopathic Cervical Dystonia (CD) - Pharmaco-Economic Impact
Status: Enrolling
Updated:  12/31/1969
Parkinson's and Movement Disorders Center of Maryland
mi
from
Elkridge, MD
Phase IV-Cervical Dystonia-INTEREST IN CD2
An International Observational Prospective Study On Long-Term Response To Botulinum Toxin Type A (BoNT-A) Injections In Subjects Suffering From Idiopathic Cervical Dystonia (CD) - Pharmaco-Economic Impact
Status: Enrolling
Updated: 12/31/1969
Parkinson's and Movement Disorders Center of Maryland
mi
from
Elkridge, MD
Click here to add this to my saved trials
Phase IV-Cervical Dystonia-INTEREST IN CD2
An International Observational Prospective Study On Long-Term Response To Botulinum Toxin Type A (BoNT-A) Injections In Subjects Suffering From Idiopathic Cervical Dystonia (CD) - Pharmaco-Economic Impact
Status: Enrolling
Updated:  12/31/1969
Tufts Medical Center
mi
from
Boston, MA
Phase IV-Cervical Dystonia-INTEREST IN CD2
An International Observational Prospective Study On Long-Term Response To Botulinum Toxin Type A (BoNT-A) Injections In Subjects Suffering From Idiopathic Cervical Dystonia (CD) - Pharmaco-Economic Impact
Status: Enrolling
Updated: 12/31/1969
Tufts Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Phase IV-Cervical Dystonia-INTEREST IN CD2
An International Observational Prospective Study On Long-Term Response To Botulinum Toxin Type A (BoNT-A) Injections In Subjects Suffering From Idiopathic Cervical Dystonia (CD) - Pharmaco-Economic Impact
Status: Enrolling
Updated:  12/31/1969
The Parkinson's and Movement Disorders Center
mi
from
Southfield, MI
Phase IV-Cervical Dystonia-INTEREST IN CD2
An International Observational Prospective Study On Long-Term Response To Botulinum Toxin Type A (BoNT-A) Injections In Subjects Suffering From Idiopathic Cervical Dystonia (CD) - Pharmaco-Economic Impact
Status: Enrolling
Updated: 12/31/1969
The Parkinson's and Movement Disorders Center
mi
from
Southfield, MI
Click here to add this to my saved trials
Phase IV-Cervical Dystonia-INTEREST IN CD2
An International Observational Prospective Study On Long-Term Response To Botulinum Toxin Type A (BoNT-A) Injections In Subjects Suffering From Idiopathic Cervical Dystonia (CD) - Pharmaco-Economic Impact
Status: Enrolling
Updated:  12/31/1969
Vanderbilt University
mi
from
Nashville, TN
Phase IV-Cervical Dystonia-INTEREST IN CD2
An International Observational Prospective Study On Long-Term Response To Botulinum Toxin Type A (BoNT-A) Injections In Subjects Suffering From Idiopathic Cervical Dystonia (CD) - Pharmaco-Economic Impact
Status: Enrolling
Updated: 12/31/1969
Vanderbilt University
mi
from
Nashville, TN
Click here to add this to my saved trials
Phase IV-Cervical Dystonia-INTEREST IN CD2
An International Observational Prospective Study On Long-Term Response To Botulinum Toxin Type A (BoNT-A) Injections In Subjects Suffering From Idiopathic Cervical Dystonia (CD) - Pharmaco-Economic Impact
Status: Enrolling
Updated:  12/31/1969
Bab El Oued Hospital
mi
from
Alger,
Phase IV-Cervical Dystonia-INTEREST IN CD2
An International Observational Prospective Study On Long-Term Response To Botulinum Toxin Type A (BoNT-A) Injections In Subjects Suffering From Idiopathic Cervical Dystonia (CD) - Pharmaco-Economic Impact
Status: Enrolling
Updated: 12/31/1969
Bab El Oued Hospital
mi
from
Alger,
Click here to add this to my saved trials
Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Arm(s) or of Arm(s) and Leg(s) in Cerebral Palsy
Prospective, Multicenter, Randomized, Double-blind, Parallel-group, Dose-response Study of Three Doses Xeomin® (incobotulinumtoxinA, NT 201) for the Treatment of Upper Limb Spasticity Alone or Combined Upper and Lower Limb Spasticity in Children and Adolescents (Age 2 - 17 Years) With Cerebral Palsy
Status: Enrolling
Updated:  12/31/1969
Merz Investigational Site #001286
mi
from
Gulf Breeze, FL
Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Arm(s) or of Arm(s) and Leg(s) in Cerebral Palsy
Prospective, Multicenter, Randomized, Double-blind, Parallel-group, Dose-response Study of Three Doses Xeomin® (incobotulinumtoxinA, NT 201) for the Treatment of Upper Limb Spasticity Alone or Combined Upper and Lower Limb Spasticity in Children and Adolescents (Age 2 - 17 Years) With Cerebral Palsy
Status: Enrolling
Updated: 12/31/1969
Merz Investigational Site #001286
mi
from
Gulf Breeze, FL
Click here to add this to my saved trials
Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Arm(s) or of Arm(s) and Leg(s) in Cerebral Palsy
Prospective, Multicenter, Randomized, Double-blind, Parallel-group, Dose-response Study of Three Doses Xeomin® (incobotulinumtoxinA, NT 201) for the Treatment of Upper Limb Spasticity Alone or Combined Upper and Lower Limb Spasticity in Children and Adolescents (Age 2 - 17 Years) With Cerebral Palsy
Status: Enrolling
Updated:  12/31/1969
Merz Investigational Site #001285
mi
from
Savannah, GA
Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Arm(s) or of Arm(s) and Leg(s) in Cerebral Palsy
Prospective, Multicenter, Randomized, Double-blind, Parallel-group, Dose-response Study of Three Doses Xeomin® (incobotulinumtoxinA, NT 201) for the Treatment of Upper Limb Spasticity Alone or Combined Upper and Lower Limb Spasticity in Children and Adolescents (Age 2 - 17 Years) With Cerebral Palsy
Status: Enrolling
Updated: 12/31/1969
Merz Investigational Site #001285
mi
from
Savannah, GA
Click here to add this to my saved trials
Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Arm(s) or of Arm(s) and Leg(s) in Cerebral Palsy
Prospective, Multicenter, Randomized, Double-blind, Parallel-group, Dose-response Study of Three Doses Xeomin® (incobotulinumtoxinA, NT 201) for the Treatment of Upper Limb Spasticity Alone or Combined Upper and Lower Limb Spasticity in Children and Adolescents (Age 2 - 17 Years) With Cerebral Palsy
Status: Enrolling
Updated:  12/31/1969
Merz Investigational Site #001186
mi
from
Chicago, IL
Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Arm(s) or of Arm(s) and Leg(s) in Cerebral Palsy
Prospective, Multicenter, Randomized, Double-blind, Parallel-group, Dose-response Study of Three Doses Xeomin® (incobotulinumtoxinA, NT 201) for the Treatment of Upper Limb Spasticity Alone or Combined Upper and Lower Limb Spasticity in Children and Adolescents (Age 2 - 17 Years) With Cerebral Palsy
Status: Enrolling
Updated: 12/31/1969
Merz Investigational Site #001186
mi
from
Chicago, IL
Click here to add this to my saved trials